Despite their unquestionable benefits, a number of observational studies have reported a not irrelevant discontinuation rate of AM in SLE and RAHerewith, we would like to highlight that AM discontinuation is quite common also in primary Sjögren’s syndrome (pSS) as well as in SLE and RA patients.
Discontinuation rates and timing of antimalarial drugs in primary Sjögren's syndrome.
BALDINI, CHIARA;Ferro F;Tani C;
2013-01-01
Abstract
Despite their unquestionable benefits, a number of observational studies have reported a not irrelevant discontinuation rate of AM in SLE and RAHerewith, we would like to highlight that AM discontinuation is quite common also in primary Sjögren’s syndrome (pSS) as well as in SLE and RA patients.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
47/03292321534607322365457478050053666667
solo utenti autorizzati
Tipologia:
Versione finale editoriale
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
103.41 kB
Formato
Unknown
|
103.41 kB | Unknown | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
